Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
4 reasons why analysts are bearish on Dr Reddy's Labs outlook after Q4
Analysts have turned cautious on Dr Reddy's Laboratories after Q4 results raised concerns over weakening US business, sharp Revlimid decline, pricing pressure and delays in semaglutide launches
Dr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy?
Dr Reddy shares swung between gains and losses in morning deals on the BSE on Wednesday, 13 May. It rose nearly 3% and then plunged 4% during the session.
Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in
Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.
Stocks to Watch for May 13: Dixon, Neuland, Torrent Power, Tata Power, Bharti Airtel and more
Tata Power, Torrent Power and Dr. Reddy's report weaker Q4, Berger Paints, Neuland Laboratories, MTAR Technologies and Kalpataru Projects post strong gains, Vodafone Idea plans fundraise. Here are few stocks to keep an eye on ahead of Wednesday's trading session.
Dr Reddy's Laboratories consolidated net profit declines 86.14% in the March 2026 quarter
Sales decline 11.64% to Rs 7516.20 crore
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore in the year ago period, an 86% YoY fall.
Dr Reddy's Q4 results 2026: Profit plunges 86% YoY to ₹220 crore; board recommends a final dividend of ₹8
Dr Reddy's Q4 results 2026: Dr Reddy's Laboratories reported a sharp 86.2% YoY fall in its consolidated net profit to ₹220.1 crore for Q4FY26. The company's board recommended a final dividend of ₹8 per share of face value of ₹1 each for FY26.
Q4 Results Today: Dr Reddy's, Tata Power, Dixon Technologies, BPCL And More — Earnings Estimates
Berger Paints India, Borosil Renewables, BPCL, Dixon Technologies and Dr. Reddy's Laboratories are among companies that will announce Q4 results today.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories demonstrates consistent performance.
Q4 Results LIVE Updates: Dr. Reddy's, Dixon report results today; Indian Hotels, Anant Raj react
Q4 Results LIVE Updates: Its an earnings-heavy day on the Dalal Street today. Nifty 50 stock Dr Reddy's Laboratories is scheduled to report its numbers today. Dixon Tech, Berger Paints, Nazara Tech, INOX India, Cohance Lifesciences, Gopal Snacks, Kalpataru, KPR Mill, Max Financial Services, MobiKwik, MTAR Tech, Novartis, Pfizer, Religare, Keystone Developers, Sagility, Tata Power, Torrent Power, Texmaco Rail, V-Guard Industries, are among the other important results to track today. Watch this space for all the LIVE earnings updates.
